home / stock / harp / harp news

HARP News and Press, Harpoon Therapeutics Inc. From 10/13/23

Stock Information
Company Name: Harpoon Therapeutics Inc.
Stock Symbol: HARP
Market: NASDAQ
Website: harpoontx.com
Menu
HARP HARP Quote HARP Short HARP News HARP Articles HARP Message Board
Get HARP Alerts

News, Short Squeeze, Breakout and More Instantly...
HARP - BPTH, HARP and BTDR among mid-day movers

2023-10-13 13:36:57 ET Gainers: Sigma Additive Solutions ( SASI ) +138% . P & F Industries ( PFIN ) +87% . Bio-Path Holdings ( BPTH ) +61% . MicroAlgo ( MLGO ) +31% . Comtech Telecommunications Corp. ( CMTL ) +29% . PSQ H...
HARP - Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328...

HARP - Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile: – 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to be presented by the end of 2023 SOUTH SAN FR...

HARP - Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HP...
HARP - MULN, STIX and WE among mid-day movers

2023-09-14 13:39:25 ET Gainers: TradeUP Acquisition Corp. ( UPTD ) +62% . PFSweb ( PFSW ) +48% . Bruush Oral Care ( BRSH ) +33% . Nikola Corporation ( NKLA ) +25% . ENDRA Life Sciences ( NDRA ) +24% . First Wave BioPharma ( ...

HARP - Harpoon up even as AbbVie declines license option for cancer asset

2023-09-13 17:22:37 ET More on Harpoon Therapeutics Seeking Alpha’s Quant Rating on Harpoon Therapeutics Historical earnings data for Harpoon Therapeutics Financial information for Harpoon Therapeutics For further details see: Harpoon up even as Ab...

HARP - FATE, MVST and PAYO are among after hour movers

2023-09-13 17:07:09 ET Gainers: The Kraft Heinz  ( KHC ) +6% . CareDx ( CDNA ) +5% . Payoneer Global ( PAYO ) +5% . Microvast Holdings ( MVST ) +4% . Fate Therapeutics ( FATE ) +4% . Losers: IBEX Limited ( IBEX )...
HARP - Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of...

HARP - Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg co...

HARP - Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023

KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for Medical Oncology (ESMO) being held October 20-24, 2023 SOUTH SAN FRAN...
Previous 10 Next 10